10 Feb
Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men (PR Newswire via Yahoo! Finance)
Posted in Sexual Dysfunction on 10.02.10 by Merlyn
Palatin Technologies, Inc. today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. Â The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. Â The study will also evaluate …